Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Inventiva (ENXTPA:IVA) stock has been relatively flat in the latest session, leaving investors focused on how its clinical stage pipeline in MASH and rare diseases, together with recent share performance, shapes the current risk reward profile.
See our latest analysis for Inventiva.
Over the past year, Inventiva's share price return has been mixed, with a 9.1% 1 month gain and a 15.4% decline over 3 months. The 1 year total shareholder return of 34.7% points to earlier buying interest that has cooled recently.
If you are weighing Inventiva's risk profile against other opportunities in the sector, it can help to see what else is moving in healthcare focused AI, starting with 130 healthcare AI stocks
So is Inventiva's recent 1 month rebound, contrasted with a weaker 3 month patch, telling you something new about its MASH focused pipeline, or mostly reflecting shifting sentiment around a clinical stage story that is still loss making?
Most Popular Narrative: 63% Undervalued
Compared with the last close at €3.73, the most widely followed narrative sets Inventiva's fair value at €10.09, putting the focus firmly on what assumptions get it there.
The ongoing Phase III clinical trial for lanifibranor in MASH is anticipated to complete patient recruitment in the first half of 2025, with top-line results expected in the second half of 2026. This positions lanifibranor potentially as the second oral drug approved for MASH in the United States, which could significantly increase revenue.
Want to see what sits behind that kind of valuation gap? The narrative leans heavily on sharp revenue growth, margin uplift and a premium future earnings multiple. The exact mix of those moving parts is what really matters.
Result: Fair Value of €10.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Inventiva story also hinges on funding and execution, with recent net losses and an auditor going concern warning keeping downside risks firmly in view.
Find out about the key risks to this Inventiva narrative.
Next Steps
Given this mix of concern and optimism around Inventiva, why wait on others to decide how it stacks up for you? Review the balance of potential upside and downside in our breakdown of 1 key reward and 4 important warning signs
Looking for more investment ideas beyond Inventiva?
If Inventiva has your attention but you also want fresh angles across the market, use the Simply Wall St Screener to quickly surface stocks that better fit your priorities.
-
Target potential mispriced opportunities by scanning a focused set of 212 high quality undervalued stocks that combine quality fundamentals with appealing price tags.
-
Strengthen the defensive side of your portfolio by reviewing 297 resilient stocks with low risk scores that score well on resilience and financial stability.
-
Get ahead of the crowd by searching through a screener containing 499 high quality undiscovered gems before more investors start paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IVA.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
